Press Releases for LGND

Press Releases
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Ligand Terminates Long-Term Lease Obligation
Ligand Pharmaceuticals Announces Second Quarter Results
Ligand and Organon Mutually Terminate Collaboration and License Agreement
Ligand to Hold Second Quarter Results Conference Call on August 3
Ligand Licenses Patents for Desulfated Heparin Technology to ParinGenix
Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders
CORRECTING and REPLACING Ligand Pharmaceuticals Announces First Quarter Results
Ligand Pharmaceuticals Announces First Quarter Results
Ligand to Hold First Quarter Results Conference Call on May 6
Ligand Announces Approval in Europe of CONBRIZA™ for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound
FABLYN® Approved in Europe for the Treatment of Osteoporosis
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results
Ligand Pharmaceuticals and The Rockefeller University Enter Settlement Agreement and Mutual Release
Ligand Enters into Screening Agreement with Trevena
Ligand to Present at BIO CEO and Investor Conference on February 9
Ligand Announces Phase IIb Results With DARA
Ligand to Hold Fourth Quarter Results Conference Call on February 12
Ligand Announces Board of Directors Changes
Ligand Completes Pharmacopeia Acquisition
Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules
Ligand Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA®
Ligand Pharmaceuticals Announces Third Quarter Results
Ligand and Pharmacopeia to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Ligand to Hold Third Quarter Results Conference Call on November 6
Ligand and Pharmacopeia to Present At the Oppenheimer 19th Annual Healthcare Conference
Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights - PrimeZone
Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights - Business Wire
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Ligand Pharmaceuticals Appoints Dr. Stephen Sabba to Board of Directors
BeaconEquity.com Issues Trade Alerts on Market Movers: WEL, LGND, PPCO, KIDS, GNLK, VCSY
Ligand Pharmaceuticals Announces Second Quarter Results
Ligand to Hold Second Quarter Results Conference Call on July 31
Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for PROMACTA(R) NDA
Ligand to Present at the Needham & Company Biotechnology and Medical Technology Conference on June 11
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
New Analyst Reports for SMURFIT STONE CONTAINER CORPORATION, INFOSYS TECHNOLOGIES LIMITED, COSTCO WHOLESALE CORP, and LIGAND PHARMACEUTICALS INCORPORATED
Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction - May 27 2008 12:42AM
Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, HealthShares(TM) Dermatology and Wound Care Index and HealthShares(TM) Orthopedic Repair Index - May 27 2008 12:42AM
Ligand Pharmaceuticals Announces First Quarter Results - Jun 2 2008 12:14AM
Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
Ligand to Hold First Quarter Results Conference Call on May 1